Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orotic Acid SCHEMBL3359468 | 0.83 | LMNA (0.66) | SLC7A5LMNAALDH1A1CYP1A2CA1 | |
| Orotic Acid SCHEMBL3359470 | 0.83 | LMNA (0.66) | SLC7A5LMNAALDH1A1CYP1A2CA1 | |
| Valine SCHEMBL3642426 | 0.74 | CRBN (0.55) | SLC7A5LMNAGRM1GRM5KDM4E | |
| Valine SCHEMBL2790124 | 0.72 | — | — | |
| Valine SCHEMBL28052598 | 0.70 | SLC7A5 (0.88) | SLC7A5LMNACYP1A2MEN1KMT2A | |
| Valine SCHEMBL2540234 | 0.70 | SLC7A5 (0.88) | SLC7A5LMNAALDH1A1ACHENR1I2 | |
| Valine SCHEMBL22471756 | 0.70 | SLC7A5 (0.88) | SLC7A5ALDH1A1PTGS1 | |
| Valine SCHEMBL4582565 | 0.70 | SLC7A5 (0.88) | SLC7A5LMNACYP1A2MEN1KMT2A | |
| Valine SCHEMBL1813972 | 0.70 | SLC7A5 (1.00) | SLC7A5ALDH1A1PTGS1 | |
| Valine SCHEMBL8516 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028104-B2 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2021-06-08 | — | — | US | disclosed |
| EP-3490996-B1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2020-08-26 | — | — | EP | disclosed |
| US-20200262847-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2020-08-20 | — | — | US | disclosed |
| US-10683309-B2 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2020-06-16 | — | — | US | disclosed |
| EP-3490996-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2019-06-05 | — | — | EP | disclosed |
| US-20190161503-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2019-05-30 | — | — | US | disclosed |
| WO-2018019917-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2018-02-01 | — | — | WO | disclosed |
| EP-3275885-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2018-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683309-B2 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | TPH1, XDH, TPH2 | SLC7A5 398/4885LMNA 3612/4885ALDH1A1 285/4885 |
| US-20190161503-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | TPH1, XDH, TPH2 | SLC7A5 398/4885LMNA 3612/4885ALDH1A1 285/4885 |
| US-20200262847-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | TPH1, XDH, TPH2 | SLC7A5 398/4885LMNA 3612/4885ALDH1A1 285/4885 |
| US-11028104-B2 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | TPH1, XDH, TPH2 | SLC7A5 398/4885LMNA 3612/4885ALDH1A1 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.